

(12) **UK Patent Application** (19) **GB** (11) **2 250 197** (13) **A**

(43) Date of A publication 03.06.1992

(21) Application No **9125268.4**

(22) Date of filing **27.11.1991**

(30) Priority data

(31) **907654**

(32) **27.11.1990**

(33) **HU**

(71) Applicant

Egis Gyógyszergyár

(Incorporated in Hungary)

30-38 Kereszturi ut, Budapest X, Hungary

(72) Inventors

Margit Nagy

Hedvig Szauder

János Egri

(74) Agent and/or Address for Service

Stephenson Harwood

**One, St. Paul's Churchyard, London, EC4M 8SH,
United Kingdom**

(51) INT CL⁵

A61K 9/08 31/54

(52) UK CL (Edition K)

**A5B BKE BLB B180 B20X B20Y B40Y B401 B41Y
B413 B50Y B502 B52Y B523 B54Y B541 B55Y
B556 B56Y B566 B57Y B576 B61Y B616 B67Y
B676 B823**

(56) Documents cited

EP 0336200 A1

(58) Field of search

UK CL (Edition K) A5B BHA BJA BKE BLB

INT CL⁵ A61K

**Online databases: WPI, DIALINDEX(MEDICINE),
CAS-ONLINE**

(54) **Pyroxycam solutions of increased stability and without tissue-damaging effect**

(57) Pyroxycam solutions of increased stability and without tissue-damaging effect, particularly solutions which can be used as injectable solutions or eye drops comprise 1 to 5 % by mass of 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide, 0.5 to 5.0 % by mass of sodium glycinecarboxylate as well as 0.5 to 12 % by mass of additive(s).

GB 2 250 197 A

- 1 -

DRUG SOLUTIONS OF INCREASED STABILITY AND WITHOUT TISSUE-
-DAMAGING EFFECT AND PROCESS FOR PREPARING SAME

5 This invention relates to novel pyroxygam solutions of increased stability and without tissue-damaging effect, particularly to solutions which are useful for injection or eye drops. The invention further relates to a process for preparing these solutions.

10 Pyroxygam, chemically 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide is an effective antiinflammatory drug which is administered mainly orally in capsule form to the patients. However, the topic injection treatment results in a more rapid
15 improvement in various inflammations of locomotor organs; therefore, there exists a demand also on injectable solutions containing pyroxygam as active ingredient. Of course, topic treatment by using eye drops containing piroxygam similarly leads to more advantageous results
20 on patients suffering from eye inflammations.

 The preparation of stable aqueous solutions is hindered by the poor water-solubility of pyroxygam. Thus, an aqueous suspension of pyroxygam is used as eye drop composition according to the Belgian patent specification No. 899,587. The suspension of the active ingredient (drug) for injections or eye drops is disad-
25
A4785-62-PT-fa

vantageous.

It has been tried to increase the solubility by salt formation with the 4-hydroxy group of pyroxy-
cam. According to the published German patent application No. 3,437,232 2 % by mass of pyroxy-
cam are dissolved at a
5 pH value of 8 to 9 in a mixture of propylene glycol, ethanol and water by adding D-(-)-N-methylglucamine. The drawback of this known injectable solution lies in that a part of the active ingredient precipitates from the solution during prolonged storage. In addition, when the
10 composition is intramuscularly administered, a tissue-damaging effect is caused by the propylene glycol being present in a concentration of about 40 % by mass.


According to the published European patent application No. 66,458 a powder ampoule is prepared from the
15 salt of pyroxy- cam formed with lysine or arginine, which is dissolved in distilled water immediately before administration. This known composition is not suitable for being used as an eye drop. The preparation of the powder ampoule in itself is relatively expensive and the work
20 of the physician also becomes cumbersome by the preparation of the solution to be injected.

According to the published German patent application No. 3,217,315 a pyroxy- cam salt is formed with an alkylglucamine, which is then dissolved in a mixture of
25 polyethylene glycol, N,N-dimethylacetamide and water while heating. The obtained solution containing an organic solvent and having a pH value of 9 to 10 exerts

a tissue-irritating action when administered intramuscularly and cannot be used as an eye drop.

The aim of the present invention is to provide a pyroxycam solution of increased stability and being free from any tissue-damaging effect.

5 Now it has been found that this aim can be achieved and a composition being useful both for injection as well as eye drop can be obtained if a solution is used which comprises 1 to 5 % by mass of 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carbox-
10 amide-1,1-dioxide, 0.5 to 5 % by mass of sodium glycine-carboxylate of the formula



and 0.5 to 12 % by mass of additive(s), preferably viscosity-increasing, surface-active and chelating
15 agents commonly used for the preparation of liquid drug formulations.

The thus-obtained aqueous solution containing 1 to 5 % by mass of pyroxycam, having a pH value of 8 to 9, remains stable at room temperature for at least 2 years
20 and does not exert any tissue-damaging effect after parenteral, e.g. intramuscular or subcutaneous, administration.

Thus the invention relates to a process for preparing the above composition, which comprises dissolving
25 in water at 80 to 100 °C 1 to 5 % by mass of 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, 0.5 to 5 % by mass of sodium glycine-

carboxylate and 0.5 to 12 % by mass of additive(s), preferably viscosity-increasing, surface-active and chelating agents commonly used for the preparation of liquid drug formulations.

Viscosity-increasing and surface-active agent(s) and a chelating substance are mainly employed as additives commonly used for the preparation of liquid drug formulations.

The viscosity-increasing agent(s), e.g. polyvinylpyrrolidone, methylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium salt, gelatine, cellulose glycolate, sorbitol and the like are usually present in a total amount of 1 to 10 % by mass in the composition. The surface-active agent(s), e.g. a polyglycol ether such as polyethyleneglycol-nonylphenol ether as well as polyethylene glycol sorbitan monolaurate, polyethylene glycol sorbitan monooleate, polyethylene glycol sorbitan monooleate, polyethylene glycol stearate, polyethylene glycol polypropylene glycol ether and the like are mostly used in a total amount of 0.01 to 1.0 % by mass.

It is suitable to use disodium ethylenediamine-tetraacetate usually in an amount of 0.01 to 0.1 % by mass as a chelating agent.

Particularly in the preparation of eye drops, bacteriostatic agent(s) such as 1,1,1-trichloro-2-methyl-2-propanol, cetylpyridinium chloride, methyl 4-hydroxybenzoate, propyl 4-hydroxybenzoate, sodium S-[ethyl-mercury(II)]thiosalicylate and the like may be incorporated

to the composition as additives maintaining the sterility of the solution. These agents are commonly used in a total amount of 0.0001 to 0.05 % by weight.

According to the process of the invention the pyroxycam solution with an increased stability and without
5 tissue-damaging effect is prepared by dissolving the additives commonly used for the preparation of liquid drug formulations and sodium glycinecarboxylate at a temperature between 90 °C and 100 °C in the main bulk of the required amount of distilled water and then dissolving
10 the pyroxycam at 90 to 100 °C in the obtained solution. After complete dissolution the final volume of the solution is adjusted by adding distilled water. Thereafter, the solution is filtered through a filter with small pore-size and filled into ampoules for injectable solu-
15 tions or into glass-droppers for eye drops. After sealing the ampoules are sterilized by heat.

Samples for the pyroxycam solution prepared according to Example 1 are being stored since 2 years. No precipitation of solid material has been observed, nor
20 have been altered the quality characteristics (colour, pH, active-ingredient content) of the solution. Thus, the solution prepared according to the invention can be maintained without any damage for at least 2 years.

The toxicity of the pyroxycam solution prepared
25 according to Example 1 was studied on rats by intramuscular administration. No perishment occurred during an observation period of 14 days following administration

of a dose of 1, 2, 5 or 8 ml/kg, respectively. Thus, the LD₅₀ value of the solution is higher than 8 ml/kg, i.e. higher than 160 mg/kg as expressed in the amount of the active ingredient. It is noted for comparison that the LD₅₀ value of a known solution containing 2 % by weight of pyroxygam, 2 % by weight of benzyl alcohol, 3 % by weight of nicotineamide, 40 % by weight of propylene glycol and distilled water was found to be 160 mg/kg.

A tissue-tolerability examination was also carried out on rats by subcutaneous administration of the pyroxygam solution prepared according to Example 1. Three male and three female rats were injected 0.3 ml of the solution each. No tissue-damaging effect was observed during an observation period of 14 days. Thus, the solution does not cause any tissue-damaging effect after administration by injection.

The process according to the invention provides a pyroxygam solution which is simple to prepare, possesses high stability, is free from any tissue-damaging effect and is suitable both for injection as well as for use as an eye-drop composition.

The invention is illustrated in detail by the following non-limiting Examples.

Example 1

0.30 g of disodium ethylenediaminetetraacetate, 50 g of polyvinylpyrrolidone (Kollidon PF 12) and 17 g of sodium glycinecarboxylate are dissolved in 900 ml of water at the boiling point. After adding 20 g of pyroxygam

and dissolving it in the solution at a temperature between 90 °C and 100 °C while stirring the solution by bubbling through gaseous nitrogen until complete dissolution, the solution is filled up to a volume of 1000 ml with distilled water and homogenized. The solution showing a pH value of 8.5 is filtered through a filter sheet with 0.45 µm pore-size and then filled into ampoules of 1 ml volume each. After sealing the ampoules are sterilized at 120 °C for 20 minutes.

Example 2

10 5 g of polyvinylpyrrolidone, 0.03 g of disodium ethylenediaminetetraacetate, 0.1 g of Pluronic(R) F-68 (polyethylene glycol polypropylene glycol ether; manufacturer: Wyandotte), 1.7 g of sodium glycinecarboxylate and 0.0001 g of sodium S-[ethyl- mercury(II)]thiosalicylate are dissolved in 90 ml of distilled water at 80 to 120 °C, then 2 g of pyroxycam are dissolved at 90 to 100 °C in the solution obtained while stirring by bubbling gaseous nitrogen through the solution. The clear solution is filled up to a volume of 100 ml with distilled 20 water, homogenized and filled into glass-droppers of 10 ml volume each. The solution obtained can be used as an eye-drop composition.

Example 3

A solution containing the components listed hereinafter is prepared as described in Example 2.

<u>Components</u>	<u>% by mass</u>
Pyroxycam	5.0

Disodium ethylenediaminetetraacetate	0.1
Sodium glycinecarboxylate	2.4
Pluronic(R) F-68	0.5
Polyvinylpyrrolidone	10.0
Sodium S-[ethyl-mercury(II)]thiosalicylate	0.01
5 Distilled water q.s.	up to 100.00

The solution obtained can be used as an eye-drop composition.

Claims:

1. A pyroxygam solution of increased stability and without tissue-damaging effect, which c o m p r i s e s 1 to 5 % by mass of 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-
5 -1,2-benzothiazine-3-carboxamide-1,1-dioxide, 0.5 to 5 % by mass of sodium glycinecarboxylate as well as 0.5 to 12.0 % by mass of additives.

2. A pyroxygam solution as claimed in claim 1, in which the additives are viscosity-increasing, surface-
10 active and/or chelating agents commonly used for the preparation of liquid drug formulations.

3. A process for the preparation of a pyroxygam solution with an increased stability and without tissue-damaging effect as claimed in claim 1, which c o m -
15 p r i s e s dissolving in water at 80 to 100 °C 1 to 5 % by mass of 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, 0.5 to 5 % by mass of sodium glycinecarboxylate and 0.5 to 12.0 % by mass of additive(s), preferably viscosity-increasing,
20 surface active and chelating agents commonly used for the preparation of liquid drug formulations.

4. A process as claimed in claim 1, in which viscosity-increasing, surface-active and/or chelating agents commonly used for the preparation of liquid drug
25 formulations are used as additives.

5. A pyroxycam solution of increased stability and without tissue-damaging effect, which comprises a therapeutically effective amount of 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide and sodium glycinecarboxylate.

5 6. A pyroxycam solution substantially as hereinbefore described in any one of Examples 1 to 3.

7. A process for the preparation of a pyroxycam solution substantially as hereinbefore described in any one of Examples 1 to 3.

- 11 -

Patents Act 1977
Examiner's report to the Comptroller under
Section 17 (The Search Report)

Application number
 9125268.4

Relevant Technical fields

(i) UK CI (Edition K) A5B(BHA, BJA, BKE, BLB)

(ii) Int CI (Edition 5) A61K

Databases (see over)

(i) UK Patent Office

(ii) ONLINE DATABASES: WPI, DIALINDEX(MEDICINE),
 CAS-ONLINE

Search Examiner

J F JENKINS

Date of Search

31 JANUARY 1992

Documents considered relevant following a search in respect of claims 1 TO 7

Category (see over)	Identity of document and relevant passages	Relevant to claim(s)
A	EP A1 0336200 (CHIESI FARMACEUTICI) see Examples 1 and 2	1

Category	Identity of document and relevant passages	Relevant to claim(s)

Categories of documents

X: Document indicating lack of novelty or of inventive step.

Y: Document indicating lack of inventive step if combined with one or more other documents of the same category.

A: Document indicating technological background and/or state of the art.

P: Document published on or after the declared priority date but before the filing date of the present application.

E: Patent document published on or after, but with priority date earlier than, the filing date of the present application.

&: Member of the same patent family, corresponding document.

Databases: The UK Patent Office database comprises classified collections of GB, EP, WO and US patent specifications as outlined periodically in the Official Journal (Patents). The on-line databases considered for search are also listed periodically in the Official Journal (Patents).